Mr. Daniel Ripley plays a central role in implementing and executing HighTide’s global business development and partnership strategy. 

Mr. Ripley has 25 years of experience in pharmaceutical business development, with a proven track record of cultivating biopharma partnerships and strategic deals. Most recently he served as Head of Global Business Development for Alpha Biopharma. During his tenure there, Mr. Ripley led partnering and in-license asset evaluation, including closing an exclusive license and collaboration agreement with Wugen Inc. for Greater China. Prior to Alpha Biopharma, Mr. Ripley led as Senior VP of Business Development, Program and Alliance Management at Conatus Pharmaceuticals. At Conatus, Mr. Ripley drove international partnering strategies and negotiated a transformational global development and commercialization agreement with Novartis to develop emricasan for nonalcoholic steatohepatitis (NASH). He also served in several senior business development roles, including Senior Director, Business Development at Apricus Biosciences and Director, Business Development at Ionis Pharmaceuticals. 

Mr. Ripley holds a Bachelor of Science degree in Microbiology and Master of Business Administration, Finance from San Diego State University.